Return to homepagePandemic Pact

Mass Screening Of Active Substances

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Principal Investigator

    Prof Dr Sandra Ciesek

  • Research Location

    Germany

  • Lead Research Institution

    Institute for Medical Virology, Fraunhofer Institute for Molecular Biology and Applied Ecology

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Researching SARS-CoV-2 and finding a drug against the disease COVID-19 is a prime example of interdisciplinary research collaborations. Right at the beginning of the pandemic, the scientists from the Institute for Medical Virology at the Frankfurt University Clinic, together with the Fraunhofer Institute for Molecular Biology and Applied Ecology, start looking for active ingredients. A huge task: within a few weeks they worked their way through so-called "compound libraries". In these pharmacological substance databases, they searched around 6,000 active substances for suitable antiviral substances that can be used against COVID-19. With a quarter of a million euros from the Johanna Quandt anniversary fund, Prof. Dr. Sandra Ciesek, Director of the Institute for Medical Virology, "With additional, qualified young scientists, we can quickly carry out the screenings and subsequent preclinical examinations. Our goal is to start clinical studies on test subjects and patients as soon as possible. "